Response to "Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped" - The Role of CYP3A4 and CYP3A5 Polymorphisms in Clinical Pharmacokinetics of Voriconazole.

Walsh, T J; Moriyama, B; Penzak, S R; Klein, T E; Caudle, K E

Walsh, T J; Moriyama, B; Penzak, S R; Klein, T E; Caudle, K E.

Afiliación

Walsh TJ; Transplantation-Oncology Infectious Diseases Program, Departments of Medicine, Pediatrics, and Microbiology and Infectious Diseases, Weill Cornell Medical Center of Cornell University, New York, New York, USA.
Moriyama B; NIH Clinical Center Pharmacy Department, Bethesda, Maryland, USA.
Penzak SR; Department of Pharmacotherapy, University of North Texas, System College of Pharmacy, Fort Worth, Texas, USA.
Klein TE; Department of Biomedical Data Science, Stanford University, Stanford, California, USA.
Caudle KE; Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Clin Pharmacol Ther ; 102(2): 190, 2017 08.

Article en En | MEDLINE | ID: mdl-28455946

Asunto(s)

Citocromo P-450 CYP2C19/genética; Voriconazol; Citocromo P-450 CYP3A/genética; Genotipo; Farmacogenética; Polimorfismo Genético

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Voriconazol / Citocromo P-450 CYP2C19 Idioma: En Revista: Clin Pharmacol Ther Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google